News & Videos - ALK-ABELLO A/S [CBOE]

ALK ( ALKB:DC / OMX: ALK B / AKBLF ): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 14 March 2024 and in line with the company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 250,000 share-based instruments for the purpose of the company’s long-term incentive plan (LTIP) for the Board of Management and key employees for 2025. The objectives of the LTIP are to incentivise and reward long-term...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ): ALK-Abelló A/S held its Annual General Meeting on 13 March 2025. The Annual General Meeting transacted the following business: Approval of the annual report 2024 and discharge of the Board of Directors and Board of Management Resolution not to declare ordinary dividend in accordance with the approved annual report for 2024 and to allocate the profits in accordance with the approved annual report Adoption of the remuneration report for 2024 Adoption of the...

ALK ( ALKB:DC / OMX: ALK B ) today announced that Health Canada has approved ALK’s ACARIZAX ® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX ® is now indicated for treatment of moderate to severe HDM-induced allergic rhinitis, with or without conjunctivitis, in children, adolescents, and adults in Canada aged five to 65. Outside Europe, Canada is one of the most important markets for ALK’s respiratory tablet portfolio with sales growing...

ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff: The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 07/2022 of 24 March 2022. The right to share options and performance shares may be achieved in March 2025, provided that ALK...

ALK ( ALKB:DC / OMX: ALK B ) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA ® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA ® is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65. ODACTRA ® is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff as set forth in the attached announcement. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 Attachment Managers...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information please contact: Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media : Maiken Riise Andersen, tel. +45 5054 1434...

ALK’s ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent the best results in the history of the company. ALK expects to continue its growth trajectory and earnings improvement in 2025. Q4 2024 highlights (Comparative figures are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated) Revenue increased by 11% to DKK...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio...

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX ® for the treatment of persistent, moderate to severe house dust mite allergic rhinitis in adults and adolescents. The recommendation paves the way for patients to gain access to ACARIZAX ® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland, now making it eligible for general reimbursement. ACARIZAX® is...

2025 financial calendar for ALK ( ALKB:DC / OMX: ALK B / AKBLF ): 22 January 2025: Silent period 19 February 2025: Annual report 2024 13 March 2025 at 4.00 p.m.: Annual General Meeting to be held at ALK Bøge Allé 1 2970 Hørsholm, Denmark Written requests to have specific business transacted at the AGM will be included in the agenda if received by the company on 29 January 2025 at the latest (may be emailed to [email protected]) 8 April 2025: Silent period 6 May 2025: Three-month interim report...

ALK’s peanut tablet shown to be safe and tolerable across multiple doses. Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses imminently. Trial expected to complete in 2026. ALK ( ALKB:DC / OMX: ALK B ) today announced positive interim results from its phase I/II clinical trial (named ‘ ALLIANCE ’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy. This part of the...

ALK ( ALKB:DC / OMX: ALK B ) today announced that its European regulatory filing for ACARIZAX ® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure. The first market introductions, including in ALK’s largest market, Germany, are expected to follow over the coming months. The data that formed the basis for the approval includes results from the largest-ever...

The reputable scientific journal, The Lancet Regional Health – Europe , has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children trial, MT-12, evaluating the efficacy and safety in children (5-11 years) with house dust mite allergic rhinitis. 1 With the acceptance for publication, ALK’s MT-12 phase 3 trial has been evaluated by the journal for its methodology, relevance, and clinical implications. This scrutiny helps...

Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales and a recovery in Jext ® sales. Europe and International markets were key contributors to growth. The operating profit improved in line with ALK’s financial ambitions, and the full-year outlook remains unchanged. Q3 performance highlights Comparative figures for Q3 2023 are shown in brackets. Revenue...

ALK ( ALKB:DC / OMX: ALK B ) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK’s new strategy Allergy+ and supports ALK’s long-term financial ambitions. Needle-free, nasal delivery of...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ) will publish its results for the first nine months (Q3) 2024 in the morning of Thursday 14 November 2024. Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff as set forth in the attached announcement. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 Attachment FM_17_24UK_27082024...

Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet sales, and improved performance of injection- and drop-based allergy immunotherapy products. ALK’s European and International markets were key contributors to growth. The increase in operating profit (EBIT) of 189% is in-line with ALK’s financial targets. Full-year outlook has been upgraded. Q2...

ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the full-year financial outlook has been upgraded to reflect the current performance and outlook for the remainder of the year. Revenue is now expected to grow by 14-16% in local currencies (prev.: 12-15%). The EBIT margin is now expected to improve to 19-21% (prev.: 18-20%) vs. 14% in 2023. The full-year revenue outlook has been upgraded primarily to reflect the strong sales of tablets and injection- and drop-based allergy immunotherapy...